USA flag logo/image

An Official Website of the United States Government

Search


Download to spreadsheetPrint
Displaying 51 – 75 of 9010 Awards
Company: APOGEE BIOTECHNOLOGY CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Radiation-induced production of pro-inflammatory and pro-fibrotic cytokines results in chronic and irreversible damage to the lungs. To date, no agent has demonstrated a sufficient safety profile to be utilized as a clinical drug for… more
Company: APPLIED BEHAVIORAL RESEARCH, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: DESCRIPTION (provided by applicant): ABR's recent series of innovative randomized trials evaluating the efficacy of various strategies for training clinicians to use evidence based therapies in alcohol and drug abuse has indicated that while both in-personworkshop and… more
Company: TRIA BIOSCIENCE CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: …estimated 40-50 million people afflicted in the US alone. AIT provides long-term benefits for the patient and its need for optimization creates a compelling business opportunity. There is a very strong rationale to develop GLA for allergy based on its superior drug profile to… more
Company: APT THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: …ntensity with time. Bone cancer pain is one of the most difficult of all persistent pains to control because the metastases are generally not limited to a single site and bone cancer pain is associated with unique pathophysiology. Nonsteroidal anti-inflammatory drugs (NSAIDs)… more
Company: ARADIGM CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: …y of CFI and DRCFI in a mouse model of M. aviumor M. abscess us lung infection; and 4) to test the same regimen as Aim 3 for M. avium in a mouse model of M. avium disseminated infection. If an efficacious treatment with CFI or DRCFI (alone or in combination with other drugs) is… more
Company: ARADIGM CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: …. One is well absorbed from the lungs and airways and excreted in urine. The other is not absorbed from the lungs and airways, but can be prepared in monodisperse insoluble particles. We accordingly propose to examine whether overnight oral administration of the first drug… more
Company: ARIETIS Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: … recent meta-analysis of clinical data showed that treatment failure is 22%. An estimated 70% of failures are due to antibiotic resistance. Considering the total number of cases, treatment failure is very high, and H. pylori is emerging as one of the most significant … more
Company: ARMAGEN TECHNOLOGIES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: … disease or Parkinson's disease. The biologic TNF inhibitors (TNFI), such as the TNF decoyreceptor, cannot be developed for brain diseases, because the TNFIs are large molecules that do not cross the blood-brain barrier (BBB). The present work continues the drug… more
Company: ARMAGEN TECHNOLOGIES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: … will develop a manufacturing plan that canbe replicated for future GMP manufacturing. The AGT-183 produced in phase II will be evaluated for safety, toxicology and pharmacokinetics in Rhesus monkeys. The completion of this work will enable entry of the AGT-183 drug development… more
Company: Thermally Targeted Therapeutics, Incorporated Agency/Program/Year/Phase: NSF / STTR / 2013 / 1
Abstract: … cancer stem cells, thereby boosting prevention of and lowering likelihood for cancer recurrence. Success in the proposed experiments would further indicate that this technology can be modified to achieve the targeted delivery of other highly specific anti-cancer drug that… more
Company: ATHERSYS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Cardiovascular disease (CVD) represents a significant unmet medical need with over 1 million patients in the United States suffering from acute myocardial infarction (AMI) each year. This epidemic of heart attacks alsorepresents a risk factor for further… more
Company: ATHERSYS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: …cal trials and novel therapeutic approaches for neurological injury. The specific objective of this SBIR Fast-Track Research Proposal is to define and successfully execute pivotal pre-clinical safety and efficacy studies required for a successful Investigational New Drug… more
Company: AURITEC PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): The broad long-term of this project is to develop methods for evaluation of adherence to intravaginal microbicide therapy for the prevention of HIV transmission. Correct determination of adherence to preventative therapies in clinical trials is essential to… more
Company: AURITEC PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): The long term goal of this project is to prevent HIV transmission. Using the drug delivery platform we developed for the ganciclovir intraocular implant, Vitrasert(R), we propose to develop an intravaginal ring microbicide formulation… more
Company: AURITEC PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: DESCRIPTION (provided by applicant): The broad long-term goal of this research is to reduce morbidity due to arthritis by developing long-lasting injectable intra-articular drug delivery systems. Intra-articular steroids have been a mainstay of treatment for arthritis for more… more
Company: TERAPIO Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: … to septicemia, increasinghospital stays and costs, and ultimately discontinuation of radiotherapy. This impacts overall effectiveness of cancer therapy so development of an agent for prevention and treatment of OM is clearly an unmet need. Terapio is developing a drug,… more
Company: AVANTGEN, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: … a panel of synapse proteins, many of which have been shown to be modulated in response to opiate administration. In this Phase I/II study, antibodies against a panel of about 150 synaptic proteins will be developed and used to probe the changes of these proteins upon drug… more
Company: AXION BIOSYSTEMS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: … liquid handling, user-friendly experiment tools, and sophisticated neural analysis software. For scientists, this integration will significantly improve their ability to extact functional information from neural cultures; paving the way for new progress in drug discovery… more
Company: BCR DIAGNOSTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: …. Milestone: Data showing sensitivity and specificity near 100%. Phase II plan: To convert the biosensor into a marketable prototype for research and clinical laboratories, and to use the prototype for a study designed to obtain 510 (k) clearance from the Food and Drug… more
Company: BEXION PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: … glioblastoma multiforme (GBM, high grade glioma), a deadly and invasive brain tumor with no effective treatment. Of the 12,000 patients expected to be diagnosed with GBM this year, most will succumb within a year. There is an urgent demand for an efficacious anti-glioma drug.… more
Company: BIOSENSE TECHNOLOGIES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: DESCRIPTION (provided by applicant): Resistance to chemotherapeutic drugs is an ongoing problem that results in eventual treatment failures or suboptimal patient outcomes. Approximately one-quarter of BCR-ABL(+) leukemia patients demonstrate evidence of resistance to imatinib… more
Company: BOLDER BIOTECHNOLOGY, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: … bone marrow cells to divide and differentiate into neutrophils. Recombinant human G-CSF is widely used to treat chemotherapy-related neutropenia in cancer patients, and recent studies indicate that it improves overall survival in animal models of ARS, although the drug… more
Company: Boulder Nonlinear Systems, Inc. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: …de-offs in manufacturability and cost to develop a variable custom manufacturing process that would including everything from simple marking to 3-D imaging using lens arrays or even constructing full holograms. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Counterfeit … more
Company: CFD Research Corporation Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: … used for both treatment of lung diseases (such as asthma and chronic obstructive pulmonary disease) and in delivering drugs to the systemic circulation. To reach the desired effectiveness and safety oforally/nasally inhaled drugs, appropriate deposition of drugs on… more
Company: CHARLESSON, LLP Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: … including VEGF, TNF- , ICAM-1 and CTGF, and inhibits multiple pathological processes of DR such as retinal vascular leakage, inflammation and neovascularization. Based on these observations, we hypothesize that 2F1mab has great potential to become an effective drug for… more
Displaying 51 – 75 of 9010 Awards
Narrow Your Search
By Agency
By Year
By Phase
By Program
By State
By Company Ownership
By Company
HELP FOR NARROW YOUR SEARCH

Search Options

There are several categories such as “By Agency”, “By Year”, “By State” etc. Select a checkbox within a category to refine your search results.

Each of your selections is listed in the “Narrow Search Filters” bar. You can uncheck these selections to remove them.


Search for Either Criteria

When you select multiple values within a category, the results will include values that match either of the selections. For example, selecting “2005” and “2007” in the “By Year” category will display results that include either 2005 OR 2007 in the results.


Narrowing the Search Results

You can refine your search results across categories. To narrow down your results, select multiple values across different categories. The results will only include values that match the selections across the categories. For example, selecting “2005” in the “By Year” category and “NASA” in the “By Agency” category will only display the results that contain both “2005” AND “NASA” in the results.